Top Markets
#1 STAU STAU +197.55%
#2 Islamic Coin Islamic Coin +157.11%
#3 Venom Venom +39.90%
#4 Backpack Backpack +32.31%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +31.35%
#6 Bitway Bitway +27.08%
#7 Falcon Finance Falcon Finance +22.26%
#8 Sonic (prev. FTM) Sonic (prev. FTM) +21.86%
#9 Nillion Nillion +18.79%
#10 Epic Chain Epic Chain +17.79%
Coin of the day
STAU STAU
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Novartis AG Novartis AG

Novartis AG

NOVN
Rangering i aksjer #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Aksjekurs
$149.90
Sist synkronisert: 2026-09-18
Markedsverdi
$284.92B
Endring (1 dag)
-0.66%
Endring (1 år)
21.93%
Land
CH
Handel Novartis AG (NOVN)

Kategori

Healthcare
P/S-forhold for Novartis AG (NOVN)
P/S-forhold per February 2026 TTM: 5.52
Ifølge Novartis AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 5.52. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Novartis AG fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
13.45 143.63%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.55 18.72%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.18 30.08%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 -15.62%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.39 -2.41%
US